Ingredient information

RiboCeine, Cellgevity and Glutathione

Posted by on Mar 12, 2015 in Cellgevity, Glutathione, Ingredients | 0 comments

In this post I’d like to introduce you to parts 2 and 3 of the Doctors Choice Interview.  In these segments Dr Don Colbert a best selling author and popular media personality and Dr Douglas Harrington – a former member of the transplant team at the internationally famous Stanford University speak about two subjects. The first subject is RiboCeine  – a breakthrough discovery/product developed by Dr Herbert Nagasawa. This is the proprietary product that Max International uses to boost glutathione.   The second part of this audio talks a little more specifically about Cellgevity – a great product for athletes, people under stress, people who are overweight or people who just want to improve their overall health with a boost in their glutathione levels.  The segment also talks about glutathione in the liver and heart – just two of the body’s organs which have a high need for glutathione.   Listen to Segment 2 and 3 by clicking on This Link  ...

Read More

New Product Packaging for Max Products

Posted by on Mar 10, 2015 in Cellgevity, Ingredients, Max N-Fuze, MAXGXL, MaxONE | 0 comments

Max International is rolling out some new product packaging . Among the first products to ship with the new designs are MaxOne and Max N-Fuze.  There’s new packaging on the way for Cellgevity as well. And there’s other changes afoot! If you’re a MaxGXl Sport user – don’t panic but Max is discontinuing that product because- in response to customer feedback they are moving all nutritional products to vegi-caps (which was the only product difference between MaxGXL and MaxGXL Sport). So now – Max GXL, MaxONE and Cellgevity will all come in vegi-caps.   I’ll get the product images on this site up to date as soon as Max International releases the new (and improved)...

Read More

RiboCeine Peer-Reviewed Research Summary

Posted by on Nov 13, 2014 in Cellgevity, Ingredients, MaxATP, MaxONE | 0 comments

NOTE: The following links take you away from this page to 3rd party research sites. 1. Jurkowska, H.; Uchacz, T.; Roberts, J.; Wrobel, M. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation Amino Acids, 2 April 2010   2. Walker, R.B.; Everette J.D., Comparative Reaction Rates of Various Antioxidants with ABTS Radical Cation. J. Agric Food Chem, 2009,57, 1156-1161.   3. Heman-Ackah, S.E.; Juhn, S.K.; Huang, T.C.; Wiedmann, T.S. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation. Otolaryngology-Head and Neck Surgery, 2010, 143, 429-434.   4. Oz, H.S.; Chen, T.S.; Nagasawa, H., Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model.Translational Research, 2007, 150(2), 122-129.   5. Lucas Slitt, A.M.; Dominick, P.K.; Roberts, J.C.; Cohen, S.D. Effect of Ribose Cysteine Pretreatment on Hepatic and Renal Acetaminophen Metabolite Formation and Glutathione Depletion. Basic Clin. Pharmacol. Toxicol., 2005, 96 (6), 487-94.   6. Lenarczyk, M.; Ueno, A.; Vannais, D.B.; Kraemer, S.; Kronenberg, A.; Roberts, J.C.; Tatsumi, K.; Hei, T.K.; Waldren, C.A. The “Pro-drug” RibCys Decreases the Mutagenicity of High-LET Radiation in Cultured Mammalian Cells. Radiation Research, 2003, 160, 579-583.   7. Wilmore, B.H.; Cassidy, P.B.; Warters, R.L.; Roberts, J.C. Thiazolidine Prodrugs as Protective Agents against y-Radiation-Induced Toxicity and Mutagenesis in V79 Cells. J. Med. Chem., 2001, 44(16), 2661-2666.   8. Lucus, A.M.; Henning G.; Dominick, P.K.; Whiteley, H.E.; Roberts, J.C.; Cohen, S.D. Ribose Cysteine Protects Against Acetaminophen-Induced Hepatic and Renal Toxicity. Toxicologic Pathology, 2000, 28(5), 697-704.   9.Roberts, J.C.; Phaneuf, H.L.; Dominick, P.K.; Wilmore, B.H.; Cassidy, P.B. Biodistribution of [35S] – Cysteine and Cysteine Prodrugs: Potential Impact on Chemoprotection Strategies. J. Labelled Cpd. Radiopharm., 1999, 42, 485-495.   10. Roberts, J.C.; Phaneuf, H.L.; Szakacs, J.G.; Zera, R.T.; Lamb, J.G.; Franklin, M.R. Differential Chemoprotection against Acetaminophen-Induced Hepatotoxicity by Latentiated L-Cysteines. Chem. Res. Toxicol., 1998, 11, 1274-1282.   11. Bantseev, V.; Bhardwaj, R.; Rathbun, W.; Nagasawa, H.T.; Trevithick, J.R. Antioxidants and Cataract: (Cataract Induction in Space Environment and Application to Terrestrial Aging Cataract). Biochem. Mol. Bio. Intl., 1997, 42, 1189-1197.   12. Roberts, J.C.; Koch, K.E.; Detrick, S.R.; Warters, R.L.; Lubec G. Thiazolidine Prodrugs of Cysteamine and Cysteine as Radioprotective Agents. Radiation Research, 1995, 143, 203-213.   13. Carroll, M.P.; Zera, R.T.; Roberts, J.C.; Schlafmann, S.E.; Feeny, D.A.; Johnston, G.R.; West, M.A.; Bubrick, M.P. Efficacy of Radioprotective Agents in Preventing Small and Large Bowel Radiation Injury. Dis. Colon Rectum, 1995, 38(7), 716-722.   14. Roberts, J.C.;Francetic, D.J.; Zera, R.T. Chemoprotection against Cyclophosphamide-Induced Urotoxicity: Comparison of Nine Thiol Protective Agents. AntiCancer Research, 1994, 14, 389-396.   15. Rowe, J.K.; Zera, R.T.; Madoff, R.D.; Fink, A.S.; Roberts, J.C.; Johnston, G.R.; Freeney, D.A.;Young, H.L.; Bubrick, M.P. Protective Effect of RibCys Following High-Dose Irradiation of the Rectosigmoid. Dis. Colon Rectum, 1993, 36(7), 681-687.   16. Roberts, J.C.; Charyulu, R. L.; Zera, R.T.; Nagasawa, H.T. Protection Against Acetaminophen Hepatotoxicity by Ribose-Cysteine (RibCys). Pharmacology & Toxicology, 1992, 70, 281-285.   17. Roberts, J.C.; Francetic, D.J. – Mechanisms of Chemoprotection by RibCys, a Thiazolidine Prodrug of L-cysteine. Med. Chem. Res.,1991, 1, 213-219.   18. Roberts, J.C.; Francetic, D.J. Time course for the elevation of glutathione in numerous organs of L1210-bearing CDF1 mice given the L-cysteine prodrug, RibCys. Toxicology Letters, 1991, 59, 245-251.   19. Roberts, J.C.; Francetic, D.J.; Zera, R.T. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity. Cancer Chemotherapy and Pharmacology 1991, 28, 166-170.   20. Roberts, J.C.; Nagasawa, H.T.; Zera, R.T.; Fricke, R.F.; Goon, D.J. W. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(polyhydroxyalky)-and 2-(Polyacetoxyalky)-Thiazolidine-4(R)-Carboxylic Acids. J. Med Chem.1987, 30, 1891-1896....

Read More

What is RiboCeine?

Posted by on Oct 27, 2012 in Glutathione, Ingredients, Nutrition | 0 comments

Finding ways to increase our levels of glutathione had kept scientists stumped for years. Since delivering glutathione directly as an oral supplement has proven to be an ineffective way to introduce it you our bodies, it was necessary to explore a different route. In response to that challenge, came the decision to supplement glutathione using its essential building blocks, the three amino acids cysteine, glutamic acid and glycine. Two of these amino acids, namely glutamic acid and glycine are readily available through our diet, but absorbing the required levels of cysteine proved to be a challenge. Until recently, NAC ( N-acetyl Cysteine) provided the best chance of maintaining ideal glutathione levels, but the large steady doses needed were expensive and inconvenient. RiboCeine changed that. Developed by the renowned medicinal chemist and research scientist , Herbert T. Nagasawa, Ph.D., tt’s a groundbreaking combination of Ribose and Cysteine. Both are naturally occuring nutrients, that when combined will effectively deliver Cysteine to your cells. RiboCeine is best described as a “demand release” nutrient that is activated by the cells themselves. After entering the bloodstream it is used by the body to produce glutathione and ATP (adenosine triphosphate). ATP is the cells natural source of energy. RiboCeine has outperformed every means of glutathione enhancement that it’s been tested against. RiboCeine is a nutritional compound and has been the topic of twenty published, peer-reviewed scientific studies. (List of studies at the bottom of the page if you click...

Read More